Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Expensive Star
617.8000 -2.75 (-0.44%)
NSE May 05, 2025 15:31 PM
Volume: 1.7M
 

617.80
-0.44%
KRChoksey
Laurus Labs’ revenue for Q4FY25 stood at INR 17,203 Mn., up 19.5% YoY (+21.6% QoQ), which was above our estimates led by strong growth in Custom Synthesis segment.
Adj. EBITDA came in at INR 4,206 Mn., up 74.2% YoY (+47.5% QoQ), led by margin improvement of 768bps YoY (+430 bps QoQ) to 24.4%.
Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.
More from Laurus Labs Ltd.
Recommended